

**To:** CN=Robert W Baker/OU=AM/O=LLY@Lilly; CN=Michael E Bandick/OU=AM/O=LLY@Lilly; CN=Suzanne F Clifford/OU=AM/O=LLY@Lilly; CN=James B Gregory/OU=AM/O=LLY@Lilly; CN=Donald P Hay/OU=AM/O=LLY@Lilly; CN=Jack E Jordan/OU=AM/O=LLY@Lilly; CN=John S Kennedy/OU=AM/O=LLY@Lilly; CN=Bruce Kinon/OU=AM/O=LLY@Lilly; CN=Michael B Murray/OU=AM/O=LLY@LILLY; CN=Virginia Stauffer/OU=AM/O=LLY@Lilly; CN=Karen Tohen/OU=AM/O=LLY@Lilly

**CC:** CN=Julie Gilmore/OU=AM/O=LLY@Lilly; CN=Bryan Johnstone/OU=AM/O=LLY@Lilly; CN=Amy J Kuntz/OU=AM/O=LLY@Lilly; CN=John R Richards/OU=AM/O=LLY@Lilly; CN=Mauricio F Tohen/OU=AM/O=LLY@Lilly

**Date:** 08/31/2000 09:09:43 AM

**From:** CN=Paula T Trzepacz/OU=AM/O=LLY

**Subject:** redistribution of medical workload for Zyprexa

Hi everyone-

I think I have spoken in person to most of you by now about redistributing the medical workload for handling important issues that affect more than one Zyprexa "silo". Please review the proposed plan below and let me know right away if you have concerns or suggestions to modify it. If everybody supports it then we will consider it the plan. If we need to tweek it I will let you know in the next week so we can move forward quickly.

Part of the problem has been that the adverse events coverage has somehow landed on one silo - the schizophrenia group - and the amount of work is too much. In addition, some of the work has already been taken up by other silos because it makes sense, but we have not formalized the accountabilities. I hope this plan will identify the primary responsibilities as well as the helpers. The primary person will be held accountable to drive the medical-marketing strategy from the medical side. These assignments will be reviewed as part of the KRA "Focus on Results" for the December PM review - we have a short time frame to make a difference. Another of the new leadership KRAs includes not taking on more than you can really do, so take that into consideration with this plan or before you volunteer for something else.

Let me or Jack know if you have ideas but need to find funding sources to make it happen.

**Proposed plan:**

Weight gain- Kinon #1, Baker #2, Hay #3

Glucose issues - Baker #1, Kinon #2, Kennedy #3

QTc issue - Kennedy and Hay share #1, Stauffer #2

Seroquel AE's cataracts and hypotension - Kennedy and Hay share #1

Prolactin (including pediatric problem) - Kinon #1

***The assumption here is that the team works across silos so that if you are not listed formally we still need your ideas and input along the way.***

We also need to identify drivers for the ***Efficacy stories*** vis a vis riperdal, seroquel and zeldox.....any ideas?

Whoever works on Seroquel issues, please contact Robert as he did a lit search up to early 1999 before we came to Lilly and has a summary he can share with you.

Thanks much- we really need to have results before the end of 1999.

Paula